Biomedical Engineering Reference
In-Depth Information
Chapter 8
Shamudheen Rafiyath,
a
Guoqing Wei,
a,b
and Delong Liu
a
a
Division of Hematology and Oncology,
New York Medical College and Westchester Medical Center,
Valhalla, NY 10595, USA
b
Bone Marrow Transplantation Center, The First Affiliated University Hospital,
Zhejiang University School of Medicine, Hangzhou 310003, China
delong_liu@nymc.edu
Chronic myeloid leukemia (CML) accounts for approximately 20%
of all adult leukemia in the United States. Progression of CML is
generally described as a three-phase process, beginning in a mostly
asymptomatic chronic phase (CP), progressing to an intermediate
accelerated phase (AP) and followed by a usually terminal blast
phase (BP). Left untreated, CML usually progresses from CP to
BP over a period of 3 to 5 years, with survival in the blastic phase
measured in months.
